TKIs Look to Solidify a Role Alongside T-DXd in the Second-Line HER2-Mutant NSCLC Setting The second-line setting for HER2-mutated NSCLC is shifting with TKIs looking to demonstrate efficacy and T-DXd under examination in the frontline now.

TKIs Look to Solidify a Role Alongside T-DXd in the Second-Line HER2-Mutant NSCLC Setting @ascocancer.bsky.social @iaslc.bsky.social #ASCO24 #ESMOASIA24 #WCLC24 #lcsm #oncology
www.onclive.com/view/tkis-lo...

Durvalumab Plus Vaccine Therapy Elicits ‘Encouraging’ DFS in BCG-Unresponsive NMIBC Durvalumab plus vaccine therapy demonstrated evidence of preliminary antitumor activity without substantial additive toxicity in BCG-unresponsive NMIBC.

Durvalumab Plus Vaccine Therapy Elicits ‘Encouraging’ DFS in BCG-Unresponsive NMIBC @myESMO #ESMOASIA24 #blcsm #oncology
www.onclive.com/view/durvalu...

Iparomlimab/Tuvonralimab Plus Chemo ± Bevacizumab Yields Responses in Recurrent/Metastatic Cervical Cancer First-line paromlimab/tuvonralimab plus chemotherapy with or without bevacizumab was active in recurrent/metastatic cervical cancer.

Iparomlimab/Tuvonralimab Plus Chemo ± Bevacizumab Yields Responses in Recurrent/Metastatic Cervical Cancer
#ESMOAsia24 #MedTwitter #cervicalcancer

onclive.com/view/iparoml...

We’re so lucky our job takes us to amazing places, collaborating with colleagues from around the world

@ascocancer.bsky.social #ESMOCancerMedComm
#ASCOBT24 #ESMOAsia24

#ESMOAsia24 #ESMO so wonderful to see old colleagues and meet new colleagues from all over #Asia with ONE FOCUS: #CancerResearch #cancer #patientcare #crcsm @vumc-insights.bsky.social #Singapore

It was a pleasure for us* to meet @michael-jefford.bsky.social who gave an excellent talk on "Improving the model of care for cancer survivors" at #ESMOAsia24

*With my friend and colleague Jiefang, The Lancet Regional Health Western Pacific

Great survivorship session at #ESMOAsia24 - thanks for having us, thanks for all who came along!

It was a pleasure to meet Dr Aju Mathew in person at the #ESMOAsia24

Do read his Correspondence published in #TheLancet Regional Health Southeast Asia

Legislation on cancer notification in India: current status
www.thelancet.com/journals/lan...

Intracranial germ cell tumours in adolescent and young adults session #ESMOAsia24 #Singapore

Multidisciplinary session on a rare entity chaired by my friend prof Giuseppe Minniti

#radonc #Neuroscience #surgonc #medonc #OncoAlert @oncoalert.bsky.social

What an honour hosting John Haanen #nki today #NCCS - talking all #celltherapy #TILtherapy & visiting our national GMP facility 👩🏻‍🔬

And a fascinating talk on myeloids in lung by @charlesswanton.bsky.social ☺️

#ESMOAsia24

Great time #ESMOAsia24 talking about oligometastatic status and multimodal treatment options for #BreastCancer at the ESMO discussion Hub

Honoured to be introduced by a great friend @kevinpunie.bsky.social

#OncoAlert @oncoalert.bsky.social

Can we bring 2L PFS closer to 12 months post 1L CDK4/6i? More work needed to improve biomarkers for selection of optimal 2L therapeutic option. #ESMOASIA24

At #ESMOAsia24 in Singapore. Big 3 days ahead!

Welcome to #ESMOASIA24
More the 4000 scientists from 68 countries in Singapore 🇸🇬

@oncoalert.bsky.social

The largest oncology conference in Asia with over 4,000 participants is about to start. #ESMOAsia24 Singapore

Last work trip / conference / invited talk for the year 😮‍💨
See you at #ESMOAsia24 ?

Coming to #ESMOAsia24? Please join us for this 'special session' on #cancer #survivorship - Sun Dec 8, 0900-1030 in Hall 407 #survonc #ayacsm